Hematological Toxicity Does Not Increase in mCRPC With Previous ERBT
The overall incidence of bone fractures with prior EBRT to the bone in patients with metastatic castration-resistant prostate cancer remains low.
Poor Liver Function HCC Population More Likely to Discontinue Regorafenib
Patients with hepatocellular carcinoma and Child-Pugh-B liver function appear to have worse overall survival following treatment with regorafenib in the REFINE trial.
Isa-KRd Produces 100% ORR in Small Newly Diagnosed Multiple Myeloma Cohort
Isatuximab plus carfilzomib, lenalidomide, and dexamethasone demonstrates durable responses in patients with newly diagnosed standard- and high-risk multiple myeloma.
Zanidatamab Combo Yields Enduring Responses in HER2+/HR+ Breast Cancer
Findings from a phase 2a study support further development of a regimen including zanidatamab, palbociclib, and fulvestrant in those with HER2-positive, hormone receptor–positive breast cancer.
Stress Management App Helps to Improve Mental Health in Those With Cancer
Results from the RESTORE study indicate that a cognitive behavioral stress management app improves symptoms of anxiety and depression.